Literature DB >> 12609369

Treatment of Childhood Idiopathic Language Deterioration with Valproate.

Gregory L. Holmes, James J. Riviello.   

Abstract

Childhood idiopathic language deterioration is a rare condition in which children lose previously gained language skills. In some children this language deterioration occurs in association with behavioral seizures or EEG epileptiform activity. The effectiveness of antiepileptic drugs in this patient population is not known. Here we retrospectively reviewed records of 57 children with childhood idiopathic language deterioration associated with seizures or epileptiform activity on their EEG who received valproate for the purpose of treating their language impairment. In 22 of the children improvement in language skills was observed. In two children language returned to normal while in the other 20 the improvement was modest. Children who responded to valproate had an earlier age of onset of the aphasia than children who were nonresponders. Seizure type, EEG findings, developmental status, and presence or absence of a frequency-modulated auditory evoked potential were not related to response. This study demonstrates that valproate can be helpful in improving language function in some children with idiopathic language deterioration associated with seizures or epileptiform activity on the EEG.

Entities:  

Year:  2001        PMID: 12609369     DOI: 10.1006/ebeh.2001.0178

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  2 in total

Review 1.  Management of Landau-Kleffner syndrome.

Authors:  Mohamad A Mikati; Alhan N Shamseddine
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior.

Authors:  Frank H Duffy; Aditi Shankardass; Gloria B McAnulty; Yaman Z Eksioglu; David Coulter; Alexander Rotenberg; Heidelise Als
Journal:  BMC Neurol       Date:  2014-05-15       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.